Amoéba Talks with Koppert extended
Amoéba announced that it continues its discussions with Dutch biocontrol leader Koppert to prepare for the commercial launch of Amoéba's biocontrol product Axpera. Initiated in December 2024, these talks have been extended to finalize contractual documentation following constructive discussions on market expectations and commercial strategies. Meanwhile, Axpera has received emergency market authorization in France for combating downy mildew in vines and exceptional authorization for use in several greenhouse crops in the Netherlands. The extended negotiations reflect both companies' commitment to a potential partnership that could entail distribution, production, registration, financing, and product development. We maintain our positive outlook and reiterate a € 1.7 target price and Buy rating.Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.